MOAB Trial: Optimal Atezolizumab for rGBM (Recurrent Glioblastoma)

Purpose of this Study

We are doing this study to find out if giving patients a drug called atezolizumab before and after surgery for recurrent glioblastoma can improve how their cancer responds.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with glioblastoma (isocitrate dehydrogenase wildtype)
  • Have a recurrence after treatment with radiation and temozolomide
  • Plan to have surgery
For more information about who can join this study, please contact the study team at 919-684-5301.

What is Involved?

Description

If you join the study, you will:
  • Have a physical exam and other tests
  • Have magnetic resonance imaging (MRI) scans of the brain
  • Have blood draws
  • Get atezolizumab before surgery
  • Get atezolizumab after surgery

Study Details

Full Title

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

Principal Investigator

Mustafa
Khasraw

Protocol Number

PRO00113395

NCT ID

NCT06069726

Phase

N/A

Enrollment Status

Open to Enrollment